Tuberculosis clinical presentation

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections have been observed in patients receiving infliximab. Some of these infections have been fatal (see Warnings). 

Harries. A.D. (1997) Tuberculosis in Africa clinical presentation and management. Pharmacol. Then. 73.1-50. 

Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, Moreno A, Gurgui A, Hayek Lumbreras C and tiie Spanish Transplantation Infection Study Groiq), GESI-TRA. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation (1997) 63, 1276-86. 

Eischl MA, Daikos GL, Uttamchandani RB, Poblete RB, Moreno IN, Reyes RR, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992 117 184-190. 

HPI KC is a 50-year-old Mexican man who presents to the clinic with upper right quadrant pain and darkMycobacterium tuberculosis (MTB). He has no other significant PMH. Medications Rifampin, isoniazid, ethambutol, and pyrazinamide. 

Although the pundits will claim that the Golden Age of Antibiotics is long past, the necessity for new agents to combat infectious disease of all types is still with us, and with the massive misuse of potent antibiotics, the microbes that are now major causes of diseases of man (and animals) are rapidly exhibiting multiresistant phenotypes. Perhaps nowhere is the effect of multiple resistance phenotype seen more than in the problems that arise in the treatment of tuberculosis. Most if not all clinical strains are resistant to at least two if not more of the conunonly used antibiotics, and currently, increasing numbers of patients present with strains... 

---